BioCentury
ARTICLE | Company News

Marketing clearance for UroVysion

August 2, 2001 7:00 AM UTC

Vysis (VYSI) received FDA marketing clearance for its UroVysion fluorescent DNA probe assay to test for recurrence of bladder cancer by detecting chromosomal abnormalities in bladder cells. The test w...